阿尔茨海默病作为一种膜功能障碍吗? 关于粉样层级推测假说的新见解
Tomas Olejar1,2, Nikol Jankovska1,2, Radoslav Matej1,2,3
1Department of Pathology and Molecular Medicine, Third Faculty of Medicine, Charles University and Thomayer Faculty Hospital, 140 59 Prague, Czech Republic.
International journal of molecular sciences
|September 14, 2024
概括
阿尔茨海默病可能源于膜功能障碍,而不仅仅是粉样质斑块. 一个新的假设表明,LRP1-Aβ42复杂问题导致陶病,提供了新的治疗点.
科学领域:
- 神经科学是一个神经科学.
- 神经病理学神经病理学
- 分子生物学分子生物学
背景情况:
- 粉样蛋白级联假说提出粉样蛋白β (Aβ) 启动阿尔茨海默病 (AD).
- 连接细胞外Aβ与细胞内tau病理的确切机制仍然不完全理解.
- 预先的神经病理学观察表明,高酸化的离子在缩性神经炎的细胞膜附近.
研究的目的:
- 为阿尔茨海默病的病原发生提出一个新的假设.
- 研究低密度脂蛋白受体相关蛋白1 (LRP1) 在AD中的作用.
- 探索Aβ聚合,LRP1和病之间的联系.
主要方法:
- 从日常神经病理学实践中的观察.
- 在初步数据的基础上制定新的假设.
- 分子相互作用的理论探索.
主要成果:
- 在神经质斑块上LRP1和纤维状Aβ42之间的假设相互作用.
- 建议LRP1-Aβ42复合体内部化的不可行性.
- 将这个复合物与膜功能障碍和随后的病症联系起来.
结论:
- 阿尔茨海默病可能被理解为一种膜功能障碍.
- 这种观点建议将LRP1-Aβ42复合体形成作为治疗策略.
- 新的治疗方法可以专注于预防Aβ42-LRP1相互作用,而不仅仅是Aβ42的产生.
相关概念视频
Alzheimer's Disease: Overview
452
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
452
Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170


